Treatment of Japanese Restless Legs Syndrome Patients with Cabergoline: An Open Clinical Preliminary Trial

Aizawa, Hitoshi; Aburakawa, Yoko; Suzuki, Yasuhiro; Enomoto, Hiroyuki; Makita, Yoshihiro; Kikuchi, Kenjiro; Kimura, Takashi; Yahara, Osamu

doi:10.2169/internalmedicine.45.1555

Cited by 2 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The studies of ropinirole, [29][30][31][32][33][34][35][36][37][38][39][40][41] pramipexole, rotigotine, [74][75][76][77][78][79][80][81][82][83][84][85] pergolide [86][87][88][89][90][91][92][93][94] and cabergoline, [95][96][97][98][99][100][101] respectively, in the treatment of iRLS are summarised by Supplementary Tables 2, 3 All these studies comparing dopamine agonists with placebo showed a significant improvement in the severity of RLS (assessed with several scales, being the most frequently used the International RLS Study Group Scale), in the IRLS frequency of "responder" rates (improvement in >50 %), in the Clinical Global Impression Improvement (CGI-I) and Patient Global Impression Improvement (PGI-I), in the quality of life (QoL) and in polysomnographic (PSG) measurements.…”

Section: Dopamine Agonistsmentioning

confidence: 99%

Treatment Options for Idiopathic Restless Legs Syndrome

Jiménez‐Jiménez¹,

Alonso‐Navarro²,

García‐Martín³

et al. 2015

European Neurological Review

View full text Add to dashboard Cite

The emergence of new effective therapies for idiopathic restless legs syndrome (iRLS) or WillisEkbom disease (WED) during the last 15 years resulted in an exponential increase of reports regarding this syndrome and, especially, treatment options. In this review, we summarise the main findings related to neuropharmacological aspects and non-pharmacological therapies of idiopathic RLS (iRLS). As was previously reported in several guidelines, dopamine agonists (fundamentally nonergotic derivatives), gabapentin and pregabalin should be considered as first-line therapies, as well as opiates as an alternative drug group. Preliminary results suggest that several non-pharmacological therapies should be promising as alternatives or adjuvants to drug treatments.

show abstract

Section: Dopamine Agonistsmentioning

confidence: 99%

Treatment Options for Idiopathic Restless Legs Syndrome

Jiménez‐Jiménez¹,

Alonso‐Navarro²,

García‐Martín³

et al. 2015

European Neurological Review

View full text Add to dashboard Cite

show abstract

Influence of Cabergoline on Motor Excitability in Patients With Restless Legs Syndrome

Gorsler¹,

Liepert²

2007

Journal of Clinical Neurophysiology

View full text Add to dashboard Cite

To investigate whether the increased urge to move the legs in restless legs syndrome (RLS) corresponds to an electrophysiological phenomenon and whether motor excitability or behavior is influenced by the treatment with a dopamine agonist. We examined 10 patients who had RLS with transcranial magnetic stimulation (TMS) before and during treatment with the dopamine agonist cabergoline. Results were compared with data obtained from healthy subjects. Inhibitory mechanisms were explored by measurement of the cortical silent period (cSP). Recordings were obtained from the right anterior tibial muscle. Clinical severity of RLS was rated using the International Restless Legs Syndrome Study Group Rating Scale (IRLSSGRS). During therapy with cabergoline, all patients reported a significant improvement of RLS symptoms. Before medication, patients showed a significant shortening of cSP compared with healthy subjects. After 14 days of treatment with cabergoline, cSP normalized in RLS patients; 90 days after the start of daily cabergoline, cSP tended to shorten again, whereas RLS symptoms further improved. There was no correlation between cSP duration and IRLSSGRS results. There were no differences in patient and control motor thresholds. These thresholds remained unchanged during treatment with cabergoline. RLS patients have a disturbance of inhibitory neurons that can temporarily be reversed with a dopamine agonist. However, the cSP does not correlate with the clinical symptoms.

show abstract

Treatment of Japanese Restless Legs Syndrome Patients with Cabergoline: An Open Clinical Preliminary Trial

Abstract: Objective

Cited by 2 publications

References 26 publications

Treatment Options for Idiopathic Restless Legs Syndrome

Treatment Options for Idiopathic Restless Legs Syndrome

Influence of Cabergoline on Motor Excitability in Patients With Restless Legs Syndrome

Contact Info

Product

Resources

About